Department of Pediatrics, Division of Hematology, McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth Houston) and Children’s Memorial Hermann Hospital; and
Auto-generated profile, based on publicly available information
Neethu M. Menon
Department of Pediatrics, Division of Hematology, McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth Houston) and Children’s Memorial Hermann Hospital; and
Giant or large coronary artery aneurysms (CAA) are rare in children, most often secondary to Kawasaki disease, and anticoagulation is recommended to prevent thromboembolism. There are no published pediatric reports on the use of a direct oral anticoagulant for this indication. We describe the anticoagulation management of an 8-year-old boy with a dilated right CAA secondary to Kawasaki disease that has remained stable on rivaroxaban and aspirin, following bleeding complications on enoxaparin and challenges on warfarin. The use of rivaroxaban appears to be safe and effective in the prevention of thrombosis in a pediatric patient with CAA.
1 October 2020 in Transfusion and Apheresis Science
Pediatric transfusions account for 5-10% of all blood transfusions administered across the country and 4.8% of hospitalized children required blood transfusions
Introduction: Inherited Hemophilia A is defined as Factor VIII (FVIII) deficiency, with levels <0.40 IU/ml. Female carriers exhibit varying degrees of X chro